collaborative meta-analysis of general and high-risk population cohorts.
A B S T R A C T
Background. Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, secondgeneration direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCVinfected patients with severe renal failure [including haemodialysis (HD) patients]. Methods. Fifty patients (36 males, mean age 6 standard deviation 60.5 6 7.5 years) with chronic HCV infection (G1: 28/56%, cirrhosis: 27/54%) and severe renal failure [i.e. MDRD estimated glomerular filtration rate (eGFR) <35 mL/min], including 35 on HD, were enrolled. Antiviral treatment consisted of SOF/ribavirin (RBV) (n ¼ 7), SOF/RBV/pegylated interferon (n ¼ 2), SOF/daclatasvir 6 RBV (n ¼ 30) or SOF/simeprevir 6 RBV (n ¼ 11) for 12 or 24 weeks. A reduced dose of SOF (400 mg three times a week or 400 mg every other day) was given to all HD patients. Initial dose of RBV (n ¼ 12) ranged from 400 to 4200 mg/week. Results. On an intent-to-treat-based analysis, sustained virological response rate was 86% at 12 weeks. During therapy, haemoglobin levels were not significantly modified, but recombinant erythropoietin (rEPO) dose significantly increased in patients treated with RBV. Two patients (4%) required blood transfusion. No patient had treatment discontinuation due to side effects. Dose of RBV was reduced in two patients (16.7%) during antiviral therapy. Dose of SOF was reduced in two non-HD patients because of side effects. In non-HD patients, median eGFR was not significantly modified during treatment. Conclusions. Our results strongly suggest that SOF-based antiviral therapy, with a reduced dose of SOF, is safe and effective for the treatment of HCV patients with ESRD, including HD patients. 
I N T R O D U C T I O N
Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). The prevalence varies worldwide, with a higher proportion of infected patients in developing countries than in developed regions. In Western countries, it has been estimated that nearly 6% of patients with ESRD on conservative therapy, between 4 and 70% patients on haemodialysis (HD) and 11-49% of kidney transplant (KTx) recipients, respectively, are infected with HCV [1] . HCV infection is well recognized as a frequent cause of morbidity, mortality and graft loss among HD and KTx patients [2] [3] [4] [5] . Therefore, viral eradication may improve the outcome of HCV-infected patients with ESRD, especially before KTx. Over the last few years, secondgeneration direct-acting antivirals (DAA) have been revolutionary in the treatment of hepatitis C. Sofosbuvir (SOF) is a potent inhibitor of the HCV NS5b (non-structural protein 5b) polymerase, which has pangenotypic activity and a high genetic barrier to resistance, and is undoubtedly the backbone of most of modern treatment strategies [6] . Since SOF is eliminated through the kidney [7] , up to now no data have been available regarding its antiviral efficacy and safety in HCV-infected patients with severe renal failure (including HD). The aim of this multicenter retrospective study was to report the preliminary experience of SOF-based antiviral therapy in a setting of ESRD.
M A T E R I A L S A N D M E T H O D S

Patients and study design
We enrolled patients at nine sites in France from October 2013 to January 2015. Eligible patients were 18 years of age or older, had chronic renal impairment [estimated glomerular filtration rate (eGFR) <35 mL/min (according to the MDRD-4 equation [8] )], chronic HCV infection and had either received previous treatment for HCV infection or had not received such treatment. There were no upper limits for age or body mass index. The evaluation of liver disease was based on a liver biopsy specimen [according to its Metavir score (on a scale of F0-F4, with higher stages indicating a greater degree of fibrosis)], FibroScan score (on a scale of 1.5-75.0 kPa, with higher scores indicating a greater degree of fibrosis) or a FibroTest score (on a scale of 0-1, with higher scores indicating more severe fibrosis). Indication for antiviral therapy was based on French recommendations at the date of initiation: mainly severe liver fibrosis, history of organ transplantation and/or extra-hepatic manifestations of HCV including chronic kidney disease. All patients were treated with SOF, and treatment regimens were at the discretion of the investigators. Antiviral treatment regimens were all used according to French recommendations at the date of initiation. In the absence of recommendations, the dose of SOF used was at each investigator's discretion. The patients were not randomized, thus, the study did not allow comparisons between treatment regimens.
Study assessments
Clinical evaluation, including signs of decompensated liver disease (ascites and hepatic encephalopathy) and laboratory tests, was performed at baseline and at scheduled visits throughout the treatment and follow-up periods at the discretion of the investigators (weeks 2, 4, 8, 12, 16, 20, 24, 28 and 36) . HCV RNA levels were measured at baseline and each visit with a realtime PCR-based assay, either COBAS AmpliPrepV R /COBAS TaqManV R (Roche Molecular Systems, Pleasanton, CA, USA) with a lower limit of quantification of 15 IU/mL or m2000SP/ m2000RT (Abbott Molecular, Des Plaines, IL, USA), with a lower limit of quantification of 12 IU/mL.
Safety
All of the patients were seen by their physician at baseline, and thereafter at the investigator's discretion. Adverse events were graded by investigators according to a modified World Health Organization grading system. Non-life-threatening adverse events and haematological disorders were managed by reducing the ribavirin (RBV) dose and/or giving recombinant erythropoietin (rEPO), authorized in France when the haemoglobin level is below 100 g/L, at the investigator's discretion.
End points
The main goal of the study was to evaluate the virological response to antiviral treatment, defined as the rate of HCV RNA under limit of quantification [end of treatment (EOT)] 4 weeks after treatment discontinuation [sustained virological response (SVR) 4] and 12 weeks after treatment discontinuation (SVR12). Secondary end points included evolution of renal function (for non-haemodialysed patients), laboratory liver tests and evaluation of safety over the full duration of treatment.
Drug monitoring
Drug monitoring was performed in the centres of Lyon and Strasbourg. Plasma concentrations of SOF (SFS) and of its main circulating metabolite, GS-331007 (GS), were determined using an ultra performance liquid chromatography (UPLC) method with tandem mass spectrometry (MS-MS) detection (Acquity system and Xevo TQ detector, Waters S.A.S. St Quentin en Yvelines, France) and a Cortecs C18þ column. The reference materials of SFS, GS and the corresponding internal standard GS13C2H3 (IS) were purchased from Alsachim (Strasbourg, France). Calibration standards were prepared by spiking blank plasma to obtain calibration standards for SFS and GS from 0.001-2.0 and 0.01-4.0 mg/L, respectively. Four levels of quality controls (QCs) were prepared. Plasma samples (standards, QCs and patient samples) were extracted by precipitation using a mixture of acetonitrile/methanol (50/50 v/v). After evaporation to dryness, the residues were reconstituted with 100 mL of methanol/H 2 O (15/85 v/v). A singly charged parent ion and a product ion were monitored under positive electrospray multiple reaction monitoring (MRM) mode for each analyte at transitions of m/z: SFS 530.23 > 243.11 and GS 261.18 > 113.05. Analyte concentrations were calculated using Masslynx software based upon a
regression analysis of calibration curves (weighted 1/x) using the ratio of analyte response to ISs response versus the analyte nominal concentration. Determination of RBV plasma trough levels was performed according to the previously reported method [9] .
Statistical analysis
Reported values represent either means (6 standard deviation) or medians (ranges). Proportions were compared by the v 2 test or Fisher's exact test. Quantitative variables were compared by the non-parametric Friedman test for serial measurements and either the Student's t-test or the Wilcoxon test. A Pvalue of <0.05 was considered to be statistically significant. All analyses were performed using SPSS software, version 13.0 (IBM, Armonk, NY, USA).
R E S U L T S
Study population
The characteristics of the study population are summarized in Table 1 .
Fifty patients with chronic hepatitis C and severe renal failure, who received a SOF-based antiviral therapy from October 2013 to January 2015, were collected from the following centres: Lyon Nord Croix Rousse University Hospital (n ¼ 13), Grenoble University Hospital (n ¼ 8), Toulouse University Hospital (n ¼ 7), Paris Cochin University Hospital (n¼ 6), Lyon Edouard Herriot University Hospital (n¼ 6), Montpellier University Hospital (n ¼ 6), Strasbourg University Hospital (n ¼ 2), Paris Tenon University Hospital (n ¼ 1) and Dijon University Hospital (n ¼ 1). Thirty-five of these 50 patients were on HD (70%). No patient had decompensated cirrhosis. Eleven patients had history of liver transplantation and 17 had history of renal transplantation. In addition, 27 patients were listed for kidney transplantation, including 2 for combined liver/kidney transplantation.
There were 36 men and 14 women, of mean age 60.5 6 7.5 years (range 37-80). All patients had detectable HCV RNA, and the majority (28/56%) had genotype (GT) 1 and severe fibrosis (34/68%). Evaluation of fibrosis was made from a liver biopsy (n ¼ 28), FibroScan (n ¼ 20) or a FibroTest (n ¼ 2). Fourteen patients (28%) were naïve of antiviral treatment. Antiviral treatment consisted of SOF/RBV (n ¼ 7), SOF/RBV/pegylated interferon (PEG-IFN) (n ¼ 2), SOF/daclatasvir (DCV) 6 RBV (n ¼ 30) or SOF/simeprevir (SMV) 6 RBV (n ¼ 11). Treatment duration was 12 or 24 weeks according to regimen. A reduced dose of SOF (400 mg 3 times a week or 400 mg every other day) was given in all HD patients. The usual dose of SOF (400 mg/ day) was given in non-HD patients. The initial dose of RBV (n ¼ 12) ranged from 57.1 to 600 mg/day.
From the entire cohort, one patient died (3rd month) from liver failure during antiviral treatment and one patient died from unknown reasons after antiviral treatment (2 months follow-up). One patient received combined liver/kidney transplantation during (3rd month) antiviral treatment. In addition, one patient received combined liver/kidney transplantation 6 months after the end of antiviral treatment.
Virological response
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels significantly improved over the treatment period from 45 IU/mL (14-147) and 48 IU/mL (13-127) at baseline to 20 IU/mL (10-45) and 21 IU/mL (10-69) at the end of treatment (P < 0.05), respectively.
On an intent-to-treat-based analysis, the response rates (HCV RNA below the limit of detection) were as follows: week 4: 36/50 (72%, HCV RNA unavailable in two patients); week 8: 45/50 (90%, HCV RNA unavailable in three patients); end of : 48/50 (96%, one patient died before week 12, one patient received liver/kidney transplantation before week 12). SVR4 was 44/50 (88%) and SVR12 was 43/50 (86%). Among the seven patients who did not achieve SVR12, one patient died before week 12, one patient received liver/kidney transplantation before week 12, one patient died after the end of treatment between follow-up weeks 4 and 12, and four patients presented with virological relapse. Patients with virological relapse (n ¼ 4) are described in detail in Table 2 .
Safety of antiviral therapy
At the beginning of antiviral therapy, haemoglobin level was 117.4 6 13.7 g/L (89-151), and 19 patients (38%) were receiving rEPO at a mean weekly dose of 15 000 6 8800 IU. During therapy, haemoglobin level was not significantly modified ( Figure 1A ). In addition to the 19 patients who were already receiving rEPO, one patient required rEPO therapy. During therapy, rEPO dose significantly increased from 15 000 IU/ week to 20 500 6 8200 IU/week ( Figure 1B ). This significant increase in rEPO dose was observed only in patients treated with RBV, without association with HD ( Figure 1C ). Three patients (6%) presented with severe anaemia (haemoglobin level <80 g/L) during antiviral therapy; two patients (4%) required blood transfusion: one patient treated with SOF/RBV/PEG-IFN and one patient intolerant to rEPO who received blood transfusions before, during and after antiviral treatment. The dose of RBV was reduced in two patients (16.7%) during antiviral therapy.
Apart from anaemia, frequent side effects included headache (n ¼ 16, 32%), asthenia (n ¼ 14, 28%), digestive discomfort (i.e. diarrhoea or nausea, n ¼ 10, 20%) or insomnia (n ¼ 8, 16%). No patient had treatment discontinuation due to side effects. The dose of SOF was reduced (by half) in two patients (non-HD) because of side effects (digestive discomfort and headache).
In non-HD patients, median eGFR was not significantly modified during treatment [29.0 mL/min (range 20-34) at baseline versus 27.0 mL/min (range 17-38) at the end of treatment].
From the subgroup of patients with history of organ transplantation, 12 were still under immunosuppressive drugs. During antiviral therapy, doses of tacrolimus (n ¼ 8), cyclosporine (n ¼ 4), everolimus (n ¼ 3) or mycophenolate mofetil (n ¼ 8) did not change significantly: 1.69 6 1.44 mg/day versus 1.75 6 1.53 mg/day for tacrolimus, 110.0 6 62.2 mg/day versus 120.0 6 61.5 mg/day for cyclosporine, 0.83 6 0.29 mg/day versus 1.02 6 0.32 mg/day for everolimus and 937.5 6 417.3 mg/ day versus 937.5 6 417.3 mg/day for mycophenolate mofetil (all P > 0.05).
Drug monitoring
GS, SOF and RBV trough levels were available in some patients of our cohort. 
D I S C U S S I O N
Because HCV infection in ESRD patients is associated with an increased risk of all-cause and liver-related mortality, particularly in those who are suitable candidates for KTx, HCVinfected ESRD patients should be considered for an antiviral therapy. The present study is, to our knowledge, the largest series of HCV patients with ESRD treated with SOF-based antiviral therapy to date. According to the evolution of standard therapy over the past two decades, HCV patients with ESRD were initially treated by standard IFNa (2a or 2b). Because RBV is mainly eliminated by the kidney and not efficiently removed by dialysis, it has long been considered a contraindication regarding the risk of drug-induced anaemia. It has been suggested that adding low doses of RBV (fixed or adapted on plasma concentrations) increases SVR rates, despite significant drop-out rates mainly due to anaemia [11] . First-generation (DAA) telaprevir and boceprevir became available in 2011 and needed to be associated with PEG-IFN and RBV. Such triple therapy was reported as feasible [12] , but was not extensively evaluated (and, thus, probably not used) because of major concerns about tolerability, especially the risk of anaemia. Second-generation DAA became available in 2013, initially including SOF, DCV and SMV. Until now, SOF has been the backbone of 'new' antiviral regimens and has been used as part of combination therapy with IFN and/or RBV, or in IFN/RBV-free regimens.
The use of SOF in ESRD patients must be discussed in light of the pharmacodynamic properties of the drug. The pharmacokinetic properties of SOF have been investigated in healthy adult volunteers, in patients with chronic hepatitis C and in patients with ESRD but not infected with HCV. SOF has a very short elimination half-life ranging 0.4-0.75 h. The predominant circulating metabolite of SOF is GS, which has no anti-HCV activity in vitro. This inactive GS is metabolized into the active triphosphate GS-461203, and this active metabolite is then dephosphorylated to form GS again. The metabolite GS exhibits a longer elimination half-life than SOF, namely 27 h. The kidney is the major organ involved in the elimination of SOF and its metabolites, since approximately 80% of recovered radioactivity is retrieved in urine after a single dose of 400 mg 14 C-SOF [7] . In patients with severe renal impairment (GFR <30 mL/min), SOF and GS area under the curve inferior (AUC) was 171 and 451% higher, respectively, in comparison with patients with normal renal function. In patients with ESRD, SOF AUC was 28% higher when SOF was administered before HD compared with 60% higher when administered after HD; similarly, GS-331007 AUC was at least a 10-and 20-fold higher, respectively, of that observed in healthy subjects. In addition, it is noteworthy that HD can efficiently remove the predominant circulating metabolite GS (53% extraction ratio) [1] . Therefore, unanswered questions regarding the use of SOF in cases of severe renal failure are: (i) what could be the consequences of SOF/GS-331007 accumulation regarding toxicity; and (ii) what could be the consequences of using reduced dose of SOF on antiviral efficacy?
Here, we report our multicentre experience of SOF-based antiviral therapy in 50 patients with ESRD. We had the opportunity to measure trough plasmatic levels of SOF and GS in some of our HD patients treated with reduced doses of SOF. Our results confirm the progressive accumulation of GS, but there was no evidence that this led to clinically relevant consequences. Very recently, Desnoyer et al. reported from a small cohort of 12 patients on HD, treated with reduced or usual doses of SOF, that the pharmacokinetics of both SOF and its metabolite GS were not significantly different [13] . Our report is not large enough, and includes a heterogeneous population, especially regarding treatment regimens, for a robust conclusion on viral efficacy to be drawn. However, results were very encouraging, with only four patients (8%) experiencing virological relapse from a cohort of patients presenting significant predictors of treatment failure (severe fibrosis and lack of response on PEG-IFN/RBV). In the TARGET cohort, an 88% SVR12 rate was reported from 17 patients with eGFR under 30 mL/ min, a result comparable to that observed in patients without severe renal failure [14] . In a small study, Kalyan Ram et al. treated 15 patients with severe renal insufficiency, including 12 on HD, infected with GT1 HCV using the standard dose of SMV and a low dose of SOF (200 mg daily or 400 mg every other day), for 12 weeks in 14 of the patients and 24 weeks in 1 patient with cirrhosis. Overall, 13 (87%) of the 15 patients achieved an SVR12 [15] . In the setting of ESRD, one of the most important adverse effects of RBV-containing regimens is anaemia; emerging combinations that do not include this drug could represent a very interesting and relevant alternative in this population. Nevertheless, RBV was used in 12 of our 50 patients (24%), with a very good tolerance (dose reduction only in two cases) when used at low dose adjusted to renal function.
Eradication of HCV infection is a major goal in patients with ESRD who require dialysis, those waiting for KTx and those who have received a kidney allograft. Indeed, although the liver fibrosis progression is slower in HD patients compared with kidney transplant patients and patients with normal kidney function [16] , HD patients' survival is significantly lower in HCV-positive patients compared with HCV-negative patients [17] [18] [19] [20] . Increased risk of death is mainly related to cardiovascular and liver disease [3, 11] . In addition, clearing HCV in this population may improve their quality of life and would decrease the risk of nosocomial transmission in dialysis units. Furthermore, it has been shown that patients who are candidates for KTx who are cleared of the virus before transplantation do not relapse after transplantation [21, 22] [4, 19, [23] [24] [25] [26] . The main causes of death in patients infected by HCV are cardiovascular disease, diabetes mellitus, sepsis and liver disease. Graft survival is also significantly lower in HCV-positive patients compared with HCV-negative patients [4, 19, 23-25, 27, 28] . This is mainly due to de novo or recurrent HCVassociated glomerular disease. In addition, HCV infection has been identified as an independent predictive factor for posttransplant diabetes mellitus after KTx [29, 30] . Finally, HCV infection is responsible for liver fibrosis progression at least in a subgroup of patients [31, 32] .
Despite promising and comprehensive results, we assume that our study had several limitations. The first one is that the sample size that was not sufficient to allow precise evaluation of patient sub-groups according to fibrosis stage, HCV GT or level of renal failure. The second limitation is that it is a cohort study with heterogeneous treatment regimens, which was not designed to determine the optimal antiviral regimen. However, due to the expected poor tolerance, IFN-free RBVfree regimens could be considered as the best options. Additional data from larger series will probably become available in the near future, in order to optimize antiviral treatment in patients with ESRD. Third, in half of our cohort, evaluation of fibrosis was based on non-invasive tests (mainly FibroScan) that have not been extensively validated in ESRD patients. Lastly, new second-generation DAA will become available, without significant renal elimination, and could eventually replace SOF in new multidrug regimens. Very recently, results in ESRD patients have been reported using ombitasvir/paritaprevir/dasabuvir (3D) and grazoprevir/elbasvir combinations [33, 34] . Pockros et al. reported preliminary results from the RUBY-I study in 20 patients: treatment-naïve, noncirrhotic, infected by GT1 HCV and presenting a stage 4 or 5 renal failure [35] . Patients received 12 weeks of 3D þ RBV (GT1a) or 3D (GT1b). All 13 patients with available data at post-treatment week 4, and all 6 patients with available data at post-treatment week 12, achieved SVR. As observed in our cohort, a majority of patients treated with RBV (9/13) had a modified RBV dose due to haemoglobin decrease, but there was no study drug discontinuation. Recent phase II and III trials using grazoprevir, an NS3/4A protease inhibitor, and elbasvir, an NS5A protein inhibitor of HCV, have shown promising results against HCV GT1, 4 and 6 infections. Roth et al. assessed this all-oral, RBV-free regimen in 224 patients, with HCV GT1 infection and stage 4-5 chronic kidney disease [179 (76%) were haemodialysed] [34] . A 99% SVR12 was observed in patients receiving the treatment for 12 weeks (115/116). Although this combination is not yet on the market, it can already be used in ESRD patients within the framework of an early access programme in some countries. The main limitation of these two combinations is their lack of efficacy in GT2 and GT3. In the near future, velpatasvir, a second-wave antiNS5a agent with potent efficacy against GT2 and GT3, should be available. However, it will be administrated in combination with SOF for 12 weeks [36] . Thus, for GT2 and GT3, therapeutic options are still limited to SOF-based regimens. The next generation of SOF-free pangenotypic antiviral agents are currently being developed. For example, a phase III study exploring the efficacy of ABT-493 and ABT-530 in ESRD patients is ongoing, but not yet available.
In conclusion, our study supports the use of SOF-based regimens for the treatment of HCV patients with ESRD, as it is for patients without severe renal failure. This needs to be confirmed by larger series.
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